BakerHicks

BakerHicks does not conduct clinical trials or have its own therapeutic programs. It specializes in the design and delivery of complex facilities for life sciences clients including those in biotech, pharma, medtech, and fine chemicals.

"From feasibility through full project delivery... we transform ideas into sustainable... processes. Using our technical skills across all platforms including upstream and downstream processing..."

"Our extended experience in the pharma, biotech, medtech... sectors makes us unique..."

"Specialising in complex infrastructure... across the full project life cycle."

BakerHicks specializes in integrated engineering consulting—including facility design/build—for pharmaceutical, biotechnology, medtech and related industries. The company does not develop drugs or medical products itself but enables commercial-scale production through advanced facility planning/execution using modern technologies like BIM. It has deep expertise supporting cell/gene therapy commercialization projects as well as monoclonal antibody/vaccine/adjuvant production sites among others. Since its founding in England in 1957 it has grown to over a thousand employees across Europe; since being acquired by Morgan Sindall Group plc it operates independently under that umbrella with an active presence especially strong in Switzerland/the UK/EU markets.